Minlan Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Minlan Yuan has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Wei Zhang
Mental Health Center, National Center for Mental Disorders, West China Hospital, Sichuan University, Chengdu, China
14 shared publications Runnan Yang
Mental Health Center, National Center for Mental Disorders, West China Hospital, Sichuan University, Chengdu, China
4 shared publicationsJia Cai
Mental Health Center, National Center for Mental Disorders, West China Hospital of Sichuan University , Chengdu, China
3 shared publicationsJiayu Du
Mental Health Center, National Center for Mental Disorders, West China Hospital, Sichuan University, Chengdu, China
3 shared publicationsWen Dang
Mental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, Chengdu, China
3 shared publications- Biao Yang
Abdominal Oncology Ward, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
2 shared publications
Latest Publications
- 13 November 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-17
Vagus-Hepatic-Creatine axis modulates manic-like behaviors via hippocampal MMP19 upregulation in bipolar disorder
- 13 November 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-17
Vagus-Hepatic-Creatine axis modulates manic-like behaviors via hippocampal MMP19 upregulation in bipolar disorder
- Open Access
- 19 October 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e340
Structural network alterations and peripheral immune-inflammatory dysregulation define distinct subtypes of major depressive disorder with prognostic implications
Background: Immune-inflammatory dysregulation and cortical structural vulnerability have been increasingly implicated in major depressive disorder (MDD). However, how they interact with each other, and whether immune heterogeneity in MDD is systematically organized by structural networks, remain unclear. Methods: Genome-wide association studies data of MDD, gray matter volume (GMV) phenotypes, and 19 immune-related traits were utilized to assess causal relationships. A prospective cohort comprising 122 patients with MDD and 66 healthy controls underwent structural magnetic resonance imaging and assessment of 40 inflammatory and immune-related markers. Individualized structural covariance network analysis, machine-learning approaches, and survival analyses were used to identify neurobiological subtypes and evaluate treatment outcomes. Results: Genetically predicted MDD was associated with lower levels of circulating IGF-1 ( p FDR = 0.013). Levels of IL-5 and leptin were negatively associated with GMV alterations in the right cingulate gyrus and bilateral putamen, respectively ( p FDR < 0.05). Structural covariance abnormalities were predominantly localized to connectivity between the default mode and limbic networks and within the limbic network in MDD, and they were classified into a hypoconnectivity subtype ( n = 49) and a hyperconnectivity subtype ( n = 73). The hypoconnectivity subtype exhibited greater anxiety and anhedonia symptoms, whereas the hyperconnectivity subtype showed broadly elevated inflammatory and immune state and achieved antidepressant response more rapidly during follow-up ( p = 0.032). Conclusions: This study supports a bidirectional immune–brain framework in MDD and suggests that structure-derived subtypes classify different immune signaling heterogeneity, which may provide a biologically informed basis for stratification and prognosis in MDD.
- 19 October 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e340
Open AccessStructural network alterations and peripheral immune-inflammatory dysregulation define distinct subtypes of major depressive disorder with prognostic implications
Background: Immune-inflammatory dysregulation and cortical structural vulnerability have been increasingly implicated in major depressive disorder (MDD). However, how they interact with each other, and whether immune heterogeneity in MDD is systematically organized by structural networks, remain unclear. Methods: Genome-wide association studies data of MDD, gray matter volume (GMV) phenotypes, and 19 immune-related traits were utilized to assess causal relationships. A prospective cohort comprising 122 patients with MDD and 66 healthy controls underwent structural magnetic resonance imaging and assessment of 40 inflammatory and immune-related markers. Individualized structural covariance network analysis, machine-learning approaches, and survival analyses were used to identify neurobiological subtypes and evaluate treatment outcomes. Results: Genetically predicted MDD was associated with lower levels of circulating IGF-1 ( p FDR = 0.013). Levels of IL-5 and leptin were negatively associated with GMV alterations in the right cingulate gyrus and bilateral putamen, respectively ( p FDR < 0.05). Structural covariance abnormalities were predominantly localized to connectivity between the default mode and limbic networks and within the limbic network in MDD, and they were classified into a hypoconnectivity subtype ( n = 49) and a hyperconnectivity subtype ( n = 73). The hypoconnectivity subtype exhibited greater anxiety and anhedonia symptoms, whereas the hyperconnectivity subtype showed broadly elevated inflammatory and immune state and achieved antidepressant response more rapidly during follow-up ( p = 0.032). Conclusions: This study supports a bidirectional immune–brain framework in MDD and suggests that structure-derived subtypes classify different immune signaling heterogeneity, which may provide a biologically informed basis for stratification and prognosis in MDD.
- Open Access
- 19 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Gut microbiota-driven metabolites modulate the development of stress-related mental disorders
Stress-related mental disorders, including depression, anxiety, and post-traumatic stress disorder, represent a major global health burden, yet their underlying biological mechanisms and effective therapeutic strategies remain incompletely understood. Growing evidence from both preclinical and clinical studies indicates that alterations in gut microbiota composition and function are closely associated with the onset and progression of these disorders. A central role of the gut microbiota is the biotransformation of dietary and host-derived substrates into diverse metabolites that enter systemic circulation and influence host physiology. In this review, we highlight gut microbiota-driven metabolites. short-chain fatty acids, amino acid-related metabolites, bile acids, and monoamine-related metabolites, as key mediators of gut-brain communication that influence neural, immune, epigenetic, and endocrine processes involved in stress-related mental disorders. We summarize emerging microbial and metabolic signatures identified in animal models and human studies. Furthermore, we discuss microbiome-targeted strategies for the prevention and treatment. However, the complexity of the gut microbiota and pronounced inter-individual variability limit causal inference from current clinical studies. Consequently, translating these findings into clinical practice will require standardized study designs, longitudinal clinical investigations, and the integration of multi-omics approaches to advance precision microbiome-based interventions for psychiatric disorders.
- 19 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessGut microbiota-driven metabolites modulate the development of stress-related mental disorders
Stress-related mental disorders, including depression, anxiety, and post-traumatic stress disorder, represent a major global health burden, yet their underlying biological mechanisms and effective therapeutic strategies remain incompletely understood. Growing evidence from both preclinical and clinical studies indicates that alterations in gut microbiota composition and function are closely associated with the onset and progression of these disorders. A central role of the gut microbiota is the biotransformation of dietary and host-derived substrates into diverse metabolites that enter systemic circulation and influence host physiology. In this review, we highlight gut microbiota-driven metabolites. short-chain fatty acids, amino acid-related metabolites, bile acids, and monoamine-related metabolites, as key mediators of gut-brain communication that influence neural, immune, epigenetic, and endocrine processes involved in stress-related mental disorders. We summarize emerging microbial and metabolic signatures identified in animal models and human studies. Furthermore, we discuss microbiome-targeted strategies for the prevention and treatment. However, the complexity of the gut microbiota and pronounced inter-individual variability limit causal inference from current clinical studies. Consequently, translating these findings into clinical practice will require standardized study designs, longitudinal clinical investigations, and the integration of multi-omics approaches to advance precision microbiome-based interventions for psychiatric disorders.
- Open Access
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1780383
The emerging role of T cells in depression
Depression is increasingly recognized as a disorder involving immune brain interactions beyond classical monoaminergic dysfunction. Among immune components, T cells have emerged as key regulators linking peripheral immune dysregulation to central neuroinflammation and impaired neuroplasticity. Accumulating clinical and preclinical evidence indicates that alterations in T cell subsets, including regulatory T cells, Th1 cells, and Th17 cells, contribute to depressive pathophysiology through coordinated effects on blood-brain barrier permeability, glial activation, cytokine signaling, and neurotrophic support. This review synthesizes current evidence on the mechanisms by which T cells migrate into the central nervous system and modulate depressive behaviors. Particular emphasis is placed on the T cell regulation of brain derived neurotrophic factor signaling, and a role for T cell derived extracellular vesicles as modulators of immune neural communication and neuroplasticity. Finally, we discuss the therapeutic implications of targeting T cells in depression, including modulation of T cell subset balance, cytokine-based interventions, microbiota immune regulation, and inhibition of pathogenic T cell trafficking into the brain. Together, these findings position T cells as central orchestrators of immune neural crosstalk and promising targets for mechanism informed immunotherapies in depression.
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1780383
Open AccessThe emerging role of T cells in depression
Depression is increasingly recognized as a disorder involving immune brain interactions beyond classical monoaminergic dysfunction. Among immune components, T cells have emerged as key regulators linking peripheral immune dysregulation to central neuroinflammation and impaired neuroplasticity. Accumulating clinical and preclinical evidence indicates that alterations in T cell subsets, including regulatory T cells, Th1 cells, and Th17 cells, contribute to depressive pathophysiology through coordinated effects on blood-brain barrier permeability, glial activation, cytokine signaling, and neurotrophic support. This review synthesizes current evidence on the mechanisms by which T cells migrate into the central nervous system and modulate depressive behaviors. Particular emphasis is placed on the T cell regulation of brain derived neurotrophic factor signaling, and a role for T cell derived extracellular vesicles as modulators of immune neural communication and neuroplasticity. Finally, we discuss the therapeutic implications of targeting T cells in depression, including modulation of T cell subset balance, cytokine-based interventions, microbiota immune regulation, and inhibition of pathogenic T cell trafficking into the brain. Together, these findings position T cells as central orchestrators of immune neural crosstalk and promising targets for mechanism informed immunotherapies in depression.
- Open Access
- 17 January 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Metabolic profiling in major depressive disorder with high psychological resilience: changes in amino acid and carbohydrate metabolism
Background: Psychological resilience varies among major depressive disorder (MDD) patients, with some exhibiting high resilience. This challenges the notion of resilience as purely protective and suggests biological heterogeneity. Both resilience and MDD have been linked to metabolic alterations, but their independent and interactive effects remain unclear. This study aims to investigate how resilience and MDD jointly affect metabolic profiles, with a focus on identifying key metabolic and pathway alterations in high-resilience MDD patients compared to healthy controls, and exploring their potential for diagnostic biomarkers. Methods: Targeted serum metabolomics using UPLC-MS/MS was conducted in MDD patients and healthy controls. Resilience was assessed via the Ego Resiliency Scale (ERS). Interaction effect analysis examined the main and interactive influences of resilience and MDD. Key metabolites in high-resilience MDD were identified by OPLS-DA and pathway enrichment. A logistic regression model with cross-validation assessed diagnostic accuracy in training and test sets. Results: A total of 271 participants were enrolled, and about one-third of MDD patients exhibited high resilience. The MDD×resilience interaction was not significant, whereas MDD showed a significant main effect on metabolite levels. Five key metabolites were identified in high-resilience individuals, with arginine, methionine, and kynurenine downregulated and threonic and erythronic acids upregulated in the high-resilience MDD group. The diagnostic model achieved an area under the curve (AUC) of 0.811 in the test set. Conclusions: MDD status—rather than psychologically resilience—was the primary driver of serum metabolic variation. In high-resilience individuals, alterations converged on amino acid pathways (driven by lower arginine, methionine, kynurenine) and pentose-glucuronate axis (with higher threonic and erythronic acids), the latter is potentially linked to redox imbalance. These features may provide novel insights into depression-related metabolic dysregulation. Clinical trial number: Not applicable.
- 17 January 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessMetabolic profiling in major depressive disorder with high psychological resilience: changes in amino acid and carbohydrate metabolism
Background: Psychological resilience varies among major depressive disorder (MDD) patients, with some exhibiting high resilience. This challenges the notion of resilience as purely protective and suggests biological heterogeneity. Both resilience and MDD have been linked to metabolic alterations, but their independent and interactive effects remain unclear. This study aims to investigate how resilience and MDD jointly affect metabolic profiles, with a focus on identifying key metabolic and pathway alterations in high-resilience MDD patients compared to healthy controls, and exploring their potential for diagnostic biomarkers. Methods: Targeted serum metabolomics using UPLC-MS/MS was conducted in MDD patients and healthy controls. Resilience was assessed via the Ego Resiliency Scale (ERS). Interaction effect analysis examined the main and interactive influences of resilience and MDD. Key metabolites in high-resilience MDD were identified by OPLS-DA and pathway enrichment. A logistic regression model with cross-validation assessed diagnostic accuracy in training and test sets. Results: A total of 271 participants were enrolled, and about one-third of MDD patients exhibited high resilience. The MDD×resilience interaction was not significant, whereas MDD showed a significant main effect on metabolite levels. Five key metabolites were identified in high-resilience individuals, with arginine, methionine, and kynurenine downregulated and threonic and erythronic acids upregulated in the high-resilience MDD group. The diagnostic model achieved an area under the curve (AUC) of 0.811 in the test set. Conclusions: MDD status—rather than psychologically resilience—was the primary driver of serum metabolic variation. In high-resilience individuals, alterations converged on amino acid pathways (driven by lower arginine, methionine, kynurenine) and pentose-glucuronate axis (with higher threonic and erythronic acids), the latter is potentially linked to redox imbalance. These features may provide novel insights into depression-related metabolic dysregulation. Clinical trial number: Not applicable.
- 18 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (4) , 1958-1969
NLRP3-mediated trained immunity of microglia is involved in the recurrence-like episode of depressive disorders
Recurrent major depression is associated with increased morbidity, suicidal behaviors and increasing neurocognitive deficits. Microglia-mediated neuroinflammatory processes deeply participate in the physiopathology of depression. In response to stress, microglia can develop trained immunity mediated by epigenetic reprogramming, which can enhance the neuro-inflammatory response to subsequent insults. Here, we investigate whether, in animal models, previous depressive-like behaviors are associated with microglial trained immunity, which increases the susceptibility of mice to stress, resulting in the reocurrence of depressive-like behaviors. In the hippocampus and after recovery of initial chronic mild stress (CMS)-induced depressive behaviors, this study discovered increased and persistent chromatin accessibility and H3K4me3 marks in genes related to proinflammatory response, but without sustaining microglial activation and neuroinflammation. Furthermore, the initial CMS induced increased H3K4me3 deposition on the promotor region of NLRP3, inducing impairments in the adult hippocampal neurogenesis and stress sensitization when mice are re-exposed to subthreshold stress (reCMS) for 2 weeks, resulting in the reocurrence of depressive-like behaviors, which could be reversed through specific knockdown of NLRP3 in hippocampal microglia. Blockade of H3K4me3-mediated NLRP3 activation via the H3K4me3 inhibitor rescued neurogenesis impairment induced by initial CMS, and ameliorated the enhanced susceptibility of mice to stress re-exposure. Collectively, initial CMS induced a NLRP3-dependent trained immunity of microglia, which was mediated by epigenetic reprogramming, facilitating the susceptibility of mice to subsequent stress, thereby contributing to the reocurrence of depressive-like behaviors. Our findings might provide a perspective strategy for the prevention and treatment of depression recurrence.
- 18 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (4) , 1958-1969
NLRP3-mediated trained immunity of microglia is involved in the recurrence-like episode of depressive disorders
Recurrent major depression is associated with increased morbidity, suicidal behaviors and increasing neurocognitive deficits. Microglia-mediated neuroinflammatory processes deeply participate in the physiopathology of depression. In response to stress, microglia can develop trained immunity mediated by epigenetic reprogramming, which can enhance the neuro-inflammatory response to subsequent insults. Here, we investigate whether, in animal models, previous depressive-like behaviors are associated with microglial trained immunity, which increases the susceptibility of mice to stress, resulting in the reocurrence of depressive-like behaviors. In the hippocampus and after recovery of initial chronic mild stress (CMS)-induced depressive behaviors, this study discovered increased and persistent chromatin accessibility and H3K4me3 marks in genes related to proinflammatory response, but without sustaining microglial activation and neuroinflammation. Furthermore, the initial CMS induced increased H3K4me3 deposition on the promotor region of NLRP3, inducing impairments in the adult hippocampal neurogenesis and stress sensitization when mice are re-exposed to subthreshold stress (reCMS) for 2 weeks, resulting in the reocurrence of depressive-like behaviors, which could be reversed through specific knockdown of NLRP3 in hippocampal microglia. Blockade of H3K4me3-mediated NLRP3 activation via the H3K4me3 inhibitor rescued neurogenesis impairment induced by initial CMS, and ameliorated the enhanced susceptibility of mice to stress re-exposure. Collectively, initial CMS induced a NLRP3-dependent trained immunity of microglia, which was mediated by epigenetic reprogramming, facilitating the susceptibility of mice to subsequent stress, thereby contributing to the reocurrence of depressive-like behaviors. Our findings might provide a perspective strategy for the prevention and treatment of depression recurrence.
- 16 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120709
Metagenomic analysis of the gut microbiota in major depressive disorder with different antidepressant efficacy: A prospective cohort study
- 16 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120709
Metagenomic analysis of the gut microbiota in major depressive disorder with different antidepressant efficacy: A prospective cohort study
- Open Access
- 12 November 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (11) , e0244725
Gut microbiota dysbiosis and metabolic perturbations of bile/glyceric acids in major depressive disorder with IBS comorbidity
Major depressive disorder (MDD) and irritable bowel syndrome (IBS) exhibit high comorbidity, yet their shared pathophysiology remains unclear. Previous studies have primarily focused on the psychological health in the IBS population, without considering psychiatric diagnoses or stratifying different psychological states, potentially leading to biased findings. This study employed multi-omics approaches to characterize gut microbiota and serum metabolites in 120 MDD patients (47 with IBS and 73 without IBS) and 70 healthy controls (HCs). MDD with IBS patients showed significantly higher depression (Hamilton depression scale [HAMD-17]) and anxiety (Hamilton anxiety scale [HAMA-14]) scores than MDD-only patients ( P < 0.05). Metagenomic sequencing of fecal samples revealed increased alpha diversity (Chao1/Shannon indices) and Firmicutes dominance in both MDD groups vs HC, while Actinobacteria enrichment specifically marked MDD with IBS. Functionally, MDD with IBS uniquely activated D-amino acid/glycerolipid metabolism pathways (Kyoto Encyclopedia of Genes and Genomes). Serum metabolomics identified comorbid-specific perturbations: downregulation of bile acids (CDCA, GCDCA, GCDCA-3S) and upregulation of glyceric acid/glutaconic acid. Our study also found that Eggerthella lenta and Clostridium scindens are differentially abundant bacteria that are involved in bile acid metabolism, and that microbial genes (e.g., K03738) are associated with glyceric acid production. These findings implicate gut microbiota-driven bile acid/glyceric acid dysregulation in MDD with IBS comorbidity, supporting the gut-brain axis as a therapeutic target for probiotics or microbiota transplantation. IMPORTANCE: Major depressive disorder (MDD) exhibits a high comorbidity rate with irritable bowel syndrome (IBS). Our study, conducted on 120 MDD patients (47 of whom were comorbid with IBS) and a control group of 70 individuals, revealed that MDD-IBS comorbid patients demonstrated significantly higher depression/anxiety scores. Multi-omics analysis indicated substantial alterations in the gut microbiota (e.g., Firmicutes , Actinobacteria ) and serum metabolites (e.g., bile acids, glyceric acid) among MDD-IBS patients, which were associated with specific metabolic pathways. Therefore, the new aspect of this study was the inclusion of patients with MDD but without IBS symptoms, which provided a deeper understanding of the intestinal microbiota dysregulation associated with comorbid IBS and MDD. These findings suggest that there may be involvement of the gut-brain axis, providing new research directions for potential therapeutic targets. CLINICAL TRIALS: This study is registered with the Chinese Clinial Trial Registry as ChiCTR2100041598 .
- 12 November 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (11) , e0244725
Open AccessGut microbiota dysbiosis and metabolic perturbations of bile/glyceric acids in major depressive disorder with IBS comorbidity
Major depressive disorder (MDD) and irritable bowel syndrome (IBS) exhibit high comorbidity, yet their shared pathophysiology remains unclear. Previous studies have primarily focused on the psychological health in the IBS population, without considering psychiatric diagnoses or stratifying different psychological states, potentially leading to biased findings. This study employed multi-omics approaches to characterize gut microbiota and serum metabolites in 120 MDD patients (47 with IBS and 73 without IBS) and 70 healthy controls (HCs). MDD with IBS patients showed significantly higher depression (Hamilton depression scale [HAMD-17]) and anxiety (Hamilton anxiety scale [HAMA-14]) scores than MDD-only patients ( P < 0.05). Metagenomic sequencing of fecal samples revealed increased alpha diversity (Chao1/Shannon indices) and Firmicutes dominance in both MDD groups vs HC, while Actinobacteria enrichment specifically marked MDD with IBS. Functionally, MDD with IBS uniquely activated D-amino acid/glycerolipid metabolism pathways (Kyoto Encyclopedia of Genes and Genomes). Serum metabolomics identified comorbid-specific perturbations: downregulation of bile acids (CDCA, GCDCA, GCDCA-3S) and upregulation of glyceric acid/glutaconic acid. Our study also found that Eggerthella lenta and Clostridium scindens are differentially abundant bacteria that are involved in bile acid metabolism, and that microbial genes (e.g., K03738) are associated with glyceric acid production. These findings implicate gut microbiota-driven bile acid/glyceric acid dysregulation in MDD with IBS comorbidity, supporting the gut-brain axis as a therapeutic target for probiotics or microbiota transplantation. IMPORTANCE: Major depressive disorder (MDD) exhibits a high comorbidity rate with irritable bowel syndrome (IBS). Our study, conducted on 120 MDD patients (47 of whom were comorbid with IBS) and a control group of 70 individuals, revealed that MDD-IBS comorbid patients demonstrated significantly higher depression/anxiety scores. Multi-omics analysis indicated substantial alterations in the gut microbiota (e.g., Firmicutes , Actinobacteria ) and serum metabolites (e.g., bile acids, glyceric acid) among MDD-IBS patients, which were associated with specific metabolic pathways. Therefore, the new aspect of this study was the inclusion of patients with MDD but without IBS symptoms, which provided a deeper understanding of the intestinal microbiota dysregulation associated with comorbid IBS and MDD. These findings suggest that there may be involvement of the gut-brain axis, providing new research directions for potential therapeutic targets. CLINICAL TRIALS: This study is registered with the Chinese Clinial Trial Registry as ChiCTR2100041598 .
- 6 August 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 111, 104654
Main manifestation of “involuntary drop attack” diagnosed as Tardive dyskinesia
- 6 August 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 111, 104654
Main manifestation of “involuntary drop attack” diagnosed as Tardive dyskinesia
- 3 February 2025
- Published by Springer Nature in Angiogenesis
- Vol. 28 (2) , 1-33
The role of liver sinusoidal endothelial cells in metabolic dysfunction-associated steatotic liver diseases and liver cancer: mechanisms and potential therapies
Liver sinusoidal endothelial cells (LSECs), with their unique morphology and function, have garnered increasing attention in chronic liver disease research. This review summarizes the critical roles of LSECs under physiological conditions and in two representative chronic liver diseases: metabolic dysfunction-associated steatotic liver disease (MASLD) and liver cancer. Under physiological conditions, LSECs act as selective barriers, regulating substance exchange and hepatic blood flow. Interestingly, LSECs exhibit contrasting roles at different stages of disease progression: in the early stages, they actively resist disease advancement and help restore sinusoidal homeostasis; whereas in later stages, they contribute to disease worsening. During this transition, LSECs undergo capillarization, lose their characteristic markers, and become dysfunctional. As the disease progresses, LSECs closely interact with hepatocytes, hepatic stellate cells, various immune cells, and tumor cells, driving processes such as steatosis, inflammation, fibrosis, angiogenesis, and carcinogenesis. Consequently, targeting LSECs represents a promising therapeutic strategy for chronic liver diseases. Relevant therapeutic targets and potential drugs are summarized in this review.
- 3 February 2025
- Published by Springer Nature in Angiogenesis
- Vol. 28 (2) , 1-33
The role of liver sinusoidal endothelial cells in metabolic dysfunction-associated steatotic liver diseases and liver cancer: mechanisms and potential therapies
Liver sinusoidal endothelial cells (LSECs), with their unique morphology and function, have garnered increasing attention in chronic liver disease research. This review summarizes the critical roles of LSECs under physiological conditions and in two representative chronic liver diseases: metabolic dysfunction-associated steatotic liver disease (MASLD) and liver cancer. Under physiological conditions, LSECs act as selective barriers, regulating substance exchange and hepatic blood flow. Interestingly, LSECs exhibit contrasting roles at different stages of disease progression: in the early stages, they actively resist disease advancement and help restore sinusoidal homeostasis; whereas in later stages, they contribute to disease worsening. During this transition, LSECs undergo capillarization, lose their characteristic markers, and become dysfunctional. As the disease progresses, LSECs closely interact with hepatocytes, hepatic stellate cells, various immune cells, and tumor cells, driving processes such as steatosis, inflammation, fibrosis, angiogenesis, and carcinogenesis. Consequently, targeting LSECs represents a promising therapeutic strategy for chronic liver diseases. Relevant therapeutic targets and potential drugs are summarized in this review.